Saori Mishima
About
Saori Mishima is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Saori Mishima has authored 36 papers receiving a total of 693 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Saori Mishima's work include Gastric Cancer Management and Outcomes (17 papers), Genetic factors in colorectal cancer (11 papers) and Cancer Genomics and Diagnostics (11 papers). Saori Mishima is often cited by papers focused on Gastric Cancer Management and Outcomes (17 papers), Genetic factors in colorectal cancer (11 papers) and Cancer Genomics and Diagnostics (11 papers). Saori Mishima collaborates with scholars based in Japan, United States and Taiwan. Saori Mishima's co-authors include Takayuki Yoshino, Kohei Shitara, Yoshiaki Nakamura, Akihito Kawazoe, Takashi Kojima, Yasutoshi Kuboki, Daisuke Kotani, Toshihiko Doi, Takeshi Kuwata and Hideaki Bando and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.
In The Last Decade
Saori Mishima
32 papers receiving 689 citations
Peers
Saori Mishima
Izuma Nakayama Japan
Salah-Eddin Al-Batran Germany
Chie‐Schin Shih United States
Kentaro Sawada Japan
Annika Ålgars Finland
S D'Emidio Italy
S-E. Al-Batran Germany
Andriy Rusyn Ukraine
Feng-yi Feng China
Joana Vieira Portugal
Citations per year, relative to Saori Mishima Saori Mishima (= 1×)
peers
Izuma Nakayama
Countries citing papers authored by Saori Mishima
Since
Specialization
Citations
This map shows the geographic impact of Saori Mishima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saori Mishima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saori Mishima more than expected).
Fields of papers citing papers by Saori Mishima
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Saori Mishima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saori Mishima. The network helps show where Saori Mishima may publish in the future.
Co-authorship network of co-authors of Saori Mishima
This figure shows the co-authorship network connecting the top 25 collaborators of Saori Mishima. A scholar is included among the top collaborators of Saori Mishima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saori Mishima. Saori Mishima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kotani, Daisuke, Hisashi Fujiwara, Naoto Fujiwara, et al.. (2024). Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study. Therapeutic Advances in Medical Oncology. 16. 12674168–12674168.
2.
Kotani, Daisuke, Saori Mishima, Akihito Kawazoe, et al.. (2024). Potential Efficacy of Shiunko for Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody-Induced Skin Fissure: A Single Institutional Case Series. Integrative Cancer Therapies. 23. 1563541098–1563541098.
3.
Yukami, Hiroki, Yoshiaki Nakamura, Saori Mishima, et al.. (2024). Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN.. Journal of Clinical Oncology. 42(3_suppl). 6–6.
4.
Bando, Hideaki, Toshihiro Yamaguchi, Seiichiro Mitani, et al.. (2024). Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition. Cancer Science. 115(3). 1014–1021.
5.
Kawazoe, Akihito, Masaru Komatsu, Saori Mishima, et al.. (2024). Safety and efficacy of perioperative FLOT regimen in Japanese patients with gastric, esophagogastric junction, or esophageal adenocarcinoma: a single-institution experience. SHILAP Revista de lepidopterología. 4. 100050–100050.
6.
Kawazoe, Akihito, Daisuke Kotani, Saori Mishima, et al.. (2023). Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience. Gastric Cancer. 26(6). 1030–1039.
7.
Mishima, Saori, Daisuke Kotani, Yoshiaki Nakamura, et al.. (2023). O4-5 Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: GALAXY study in the CIRCULATE-Japan. Annals of Oncology. 34. S1385–S1385.
8.
Sawada, Kentaro, Daisuke Kotani, Hiroki Yukami, et al.. (2022). Definitive chemoradiotherapy has comparable survival outcomes to esophagectomy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: real-world data. International Journal of Clinical Oncology. 27(8). 1279–1288.
9.
Mukohara, Toru, Miki Kondo, Kazushi Maruo, et al.. (2022). Effectiveness of an online support program to help female cancer patients manage their health and illness: Protocol for a randomized controlled trial. Contemporary Clinical Trials Communications. 30. 101035–101035.
10.
Aoki, Yu, Akihito Kawazoe, Yohei Kubota, et al.. (2022). Characteristics and clinical outcomes of patients with advanced gastric or gastroesophageal cancer treated in and out of randomized clinical trials of first-line immune checkpoint inhibitors. International Journal of Clinical Oncology. 27(9). 1413–1420.
11.
Taniguchi, Hiroya, Yoshiaki Nakamura, Daisuke Kotani, et al.. (2021). CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Science. 112(7). 2915–2920.
12.
Mishima, Saori & Kohei Shitara. (2021). Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Expert Opinion on Biological Therapy. 21(7). 825–830.
13.
Okuyama, Hiroyuki, Yoshinori Kagawa, Toshiki Masuishi, et al.. (2021). Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. International Journal of Clinical Oncology. 26(11). 2025–2028.
14.
Sasaki, Akinori, Akihito Kawazoe, Saori Mishima, et al.. (2020). Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open. 5(4). e000775–e000775.
15.
Kubota, Yohei, Akihito Kawazoe, Akinori Sasaki, et al.. (2020). The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clinical Cancer Research. 26(14). 3784–3790.
16.
Yukami, Hiroki, Saori Mishima, Daisuke Kotani, et al.. (2020). P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan (trial in progress). Annals of Oncology. 31. S128–S129.
17.
Sasaki, Akinori, Yoshiaki Nakamura, Saori Mishima, et al.. (2019). Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 22(4). 793–802.
18.
Mishima, Saori, Akihito Kawazoe, Yoshiaki Nakamura, et al.. (2019). Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. Journal for ImmunoTherapy of Cancer. 7(1). 24–24.
19.
Mishima, Saori, Hiroya Taniguchi, Kiwamu Akagi, et al.. (2019). Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition. International Journal of Clinical Oncology. 25(2). 217–239.
20.
Mishima, Saori, Akihito Kawazoe, Hiroshi Matsumoto, et al.. (2018). Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. ESMO Open. 3(7). e000443–e000443.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Izuma Nakayama Breakdown of academic impact, for papers by Salah-Eddin Al-Batran Breakdown of academic impact, for papers by Chie‐Schin Shih Breakdown of academic impact, for papers by Kentaro Sawada Breakdown of academic impact, for papers by Annika Ålgars Breakdown of academic impact, for papers by S D'Emidio Breakdown of academic impact, for papers by S-E. Al-Batran Breakdown of academic impact, for papers by Andriy Rusyn Breakdown of academic impact, for papers by Feng-yi Feng Breakdown of academic impact, for papers by Joana Vieira